Pediatric Cancer, Volume 2
Kurzinformation
inkl. MwSt. Versandinformationen
Artikel zZt. nicht lieferbar
Artikel zZt. nicht lieferbar

Beschreibung
A general introduction to the principles of diagnosis and treatment of children with brain tumors is presented. Molecular characterization of solid tumors is also presented. Molecular pathways provide putative targets for new therapies. High resolution magic spinning NMR spectroscopy is explained, which is used to determine metabolic profiles for small pieces of intact tissue and whole cells in culture. The differences between adult and pediatric brain tumors are outlined. It is emphasized that pediatric low-grade gliomas need lower doses of antidrugs such as cisplatin/etoposide. It is explained that tumor suppressor genes and oncogenes play a crucial role in the development and progression of human malignancies, including those in children. Neurofibromatosis type-1 is a common genetic disorder with a high prevalence in CNS abnormalities including tumors in children; which is discussed in detail. Various neuroradiological imaging modalities in children with leukemia are detailed. Also are detailed results of clinical trials in pediatric brain tumors, such as medulloblastoma, ependymoma, craniopharyngioma, low-grade glioma, high-grade glioma, brainstem glioma, and germ cell tumors, using radiotherapy. Considering the clinical importance of epilepsy in the primary brain tumors in children, its symptoms, diagnosis, and treatments (surgery and antiepileptic drugs) are discussed. von Hayat, M. A.
Produktdetails
So garantieren wir Dir zu jeder Zeit Premiumqualität.
Über den Autor
- paperback
- 304 Seiten
- Erschienen 2010
- Springer US
- Gebunden
- 576 Seiten
- Erschienen 2017
- Springer
- paperback
- 160 Seiten
- Erschienen 2012
- American College of Physicians
- Gebunden
- 4264 Seiten
- Erschienen 2019
- Elsevier
- hardcover
- 1378 Seiten
- Erschienen 2014
- McGraw-Hill Medical
- hardcover
- 1875 Seiten
- Erschienen 2011
- Saunders
- Gebunden
- 850 Seiten
- Erschienen 2019
- Elsevier
- hardcover
- 2208 Seiten
- Erschienen 2004
- Mosby
- Gebunden
- 456 Seiten
- Erschienen 2005
- Thieme
- perfect -
- Erschienen 1997
- Hogrefe Verlag
- hardcover
- 215 Seiten
- Erschienen 1997
- Springer
- Gebunden
- 2448 Seiten
- Erschienen 2018
- Lippincott Williams&Wilki
- Kartoniert
- 168 Seiten
- Erschienen 2018
- Hogrefe AG
- hardcover -
- Erschienen 2004
- Novartis Pharma
- Gebunden
- 768 Seiten
- Erschienen 2021
- Elsevier
- Hardcover -
- Erschienen 2009
- Springer
- hardcover
- 1916 Seiten
- Erschienen 2009
- Springer
- paperback
- 388 Seiten
- Erschienen 2002
- Hogrefe Verlag
- perfect
- 280 Seiten
- Erschienen 2025
- Brandes & Apsel




